郝板栗《千金小姐》免费完整版 ,年轻的瘦了3,新上任的秘书和上司电视剧剧情介绍

RSV604

NMR下載 COA and HPLC MSDS下載
names：
RSV604
CAS號：
676128-63-5
MDL Number： MFCD28963952
MF(分子式)： C22H17FN4O2 MW(分子量)： 388.39
EINECS:No data available Reaxys Number:No data available
Pubchem ID:5279172 Brand:BIOFOUNT

RSV604(676128-63-5)是一種新型的苯二氮卓類產品。RSV604是RSV病毒復制抑制劑，EC50值0.86uM，RSV核蛋白抑制劑。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000871-10mg	10mg	99.8%	￥ 1366.00	￥ 1366.00		2-3天	- +	￥ 0.00
YZM000871-5mg	5mg	99.8%	￥ 780.00	￥ 780.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	RSV604(676128-63-5);RSV 604;RSV-604
英文別名	RSV604,676128-63-5
CAS號	676128-63-5
Inchi	InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m1/s1
InchiKey	MTPVBMVUENFFLL-HXUWFJFHSA-N
分子式 Formula	C22H17FN4O2
分子量 Molecular Weight	388.39
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 195 mg/mL(502.07 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	固體粉末,Power
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 /溶液中:-80°C 6 months月 -20°C 1 month月

RSV604(676128-63-5)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染

RSV604(676128-63-5) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:RSV604(676128-63-5),RSV604試劑,RSV604抑制劑,RSV604的雜質,RSV604的純度,RSV604的含量,RSV604的作用,RSV604的使用,RSV604的合成,RSV604的外觀,RSV604的溶解度,RSV604的生產,RSV604的產量,RSV604的MSDS

產品說明	RSV604(676128-63-5)是一種新型的苯二氮卓類產品。RSV604是RSV病毒復制抑制劑，EC50值0.86uM，RSV核蛋白抑制劑。
Introduction	RSV604 (676128-63-5) is a new type of benzodiazepine products. RSV604 is an inhibitor of RSV virus replication, with an EC50 value of 0.86uM, RSV nucleoprotein inhibitor.
Application1
Application2
Application3

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults.(Current Infectious Disease Reports,2013)

Respiratory Syncytial Virus Disease: Prevention and Treatment.(Challenges and Opportunities for Respiratory Syncytial Virus Vaccines，2013）

Human Respiratory Syncytial Virus: An Introduction,(Human Respiratory Syncytial Virus,2016)

Antiviral activity of diarylheptanoid stereoisomers against respiratory syncytial virus in vitro and in vivo.(Journal of Natural Medicines,2013)

Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion: A Focus on Respiratory Syncytial Virus.(Protein-Protein Interactions,2012)

1.Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future.
Weisman LE Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):223-33.
Abstract:Respiratory syncytial virus (RSV) is a very important pathogen worldwide. It occurs and recurs naturally throughout life. Both short and long term morbidity, and mortality are particularly significant for infants, especially those infants with underlying conditions and risk factors. Current treatment strategies for these patients (e.g Ribavirin) are limited but several new interventions (e.g. RSV604, BTA9881, ALN-RSV01) are under investigation. Several preventive agents and strategies have been developed (e.g. RSV-IGIV, palivizumab) and others are in the pipeline (e.g. motavizumab) and under development (e,g, Medi-557). In this article, we review the RSV clinical condition with a focus on the highest risk populations. In addition we review prevention and treatment strategies of the past, present and future for these high-risk patients. This review should provide a single valuable source of information to clinicians and investigators.

2.1,4-Benzodiazepines as inhibitors of respiratory syncytial virus.
Carter MC;Alber DG;Baxter RC;Bithell SK;Budworth J;Chubb A;Cockerill GS;Dowdell VC;Henderson EA;Keegan SJ;Kelsey RD;Lockyer MJ;Stables JN;Wilson LJ;Powell KL J Med Chem. 2006 Apr 6;49(7):2311-9.
Abstract:Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as a serious threat to patient groups with poorly functioning immune systems. Our approach to finding a novel inhibitor of this virus was to screen a 20 000-member diverse library in a whole cell XTT assay. Parallel assays were carried out in the absence of virus in order to quantify any associated cell toxicity. This identified 100 compounds with IC(50)'s less than 50 muM. A-33903 (18), a 1,4-benzodiazepine analogue, was chosen as the starting point for lead optimization. This molecule was moderately active and demonstrated good pharmacokinetic properties. The most potent compounds identified from this work were A-58568 (47), A-58569 (44), and A-62066 (46), where modifications to the aromatic substitution enhanced potency, and A-58175 (42), where the amide linker was modified.

3.RSV604, a novel inhibitor of respiratory syncytial virus replication.
Chapman J;Abbott E;Alber DG;Baxter RC;Bithell SK;Henderson EA;Carter MC;Chambers P;Chubb A;Cockerill GS;Collins PL;Dowdell VC;Keegan SJ;Kelsey RD;Lockyer MJ;Luongo C;Najarro P;Pickles RJ;Simmonds M;Taylor D;Tyms S;Wilson LJ;Powell KL Antimicrob Agents Chemother. 2007 Sep;51(9):3346-53. Epub 2007 Jun 18.
Abstract:Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections worldwide, yet no effective vaccine or antiviral treatment is available. Here we report the discovery and initial development of RSV604, a novel benzodiazepine with submicromolar anti-RSV activity. It proved to be equipotent against all clinical isolates tested of both the A and B subtypes of the virus. The compound has a low rate of in vitro resistance development. Sequencing revealed that the resistant virus had mutations within the nucleocapsid protein. This is a novel mechanism of action for anti-RSV compounds. In a three-dimensional human airway epithelial cell model, RSV604 was able to pass from the basolateral side of the epithelium effectively to inhibit virus replication after mucosal inoculation. RSV604, which is currently in phase II clinical trials, represents the first in a new class of RSV inhibitors and may have significant potential for the effective treatment of RSV disease.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開